Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797146 | 0.91 | RORC (0.83) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL16797187 | 0.90 | RORC (0.82) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL16810687 | 0.90 | RORC (0.81) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL16797235 | 0.89 | RORC (0.81) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL16797140 | 0.89 | RORC (0.81) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL16797139 | 0.88 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL16797183 | 0.87 | RORC (1.00) | RORCCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL19831278 | 0.86 | RORC (0.75) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL18268164 | 0.86 | RORC (0.75) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL16797234 | 0.85 | RORC (0.74) | RORCCYP2C9CYP3A4CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080090-B1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-01-31 | — | — | EP | claimed |
| US-9682977-B2 | Bicyclic heteroaryl indole analogues useful as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-06-20 | — | — | US | claimed |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-11-10 | — | — | US | claimed |
| EP-3080090-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2016-10-19 | — | — | EP | claimed |
| WO-2015087234-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-06-18 | — | — | WO | claimed |
| EP-3080090-B1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-01-31 | — | — | EP | disclosed |
| EP-3080090-B1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-9682977-B2 | Bicyclic heteroaryl indole analogues useful as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682977-B2 | Bicyclic heteroaryl indole analogues useful as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682977-B2 | Bicyclic heteroaryl indole analogues useful as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-06-20 | — | — | US | disclosed |
| WO-2016193894-A1 | TREATMENT OF RESPIRATORY DISORDERS USING ROR- GAMMA INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-12-08 | — | — | WO | disclosed |
| US-20160346234-A1 | TREATMENT OF RESPIRATORY DISORDERS USING ROR-GAMMA INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160346234-A1 | TREATMENT OF RESPIRATORY DISORDERS USING ROR-GAMMA INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-11-10 | — | — | US | disclosed |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-11-10 | — | — | US | disclosed |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-11-10 | — | — | US | disclosed |
| EP-3080090-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015087234-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015087234-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346234-A1 | TREATMENT OF RESPIRATORY DISORDERS USING ROR-GAMMA INHIBITORS | RORA, RORB, RORC | RORC 3/4885CYP2C9 993/4885CYP3A4 755/4885 |
| US-20160326163-A1 | BICYCLIC HETEROARYL INDOLE ANALOGUES USEFUL AS ROR GAMMA MODULATORS | RORA, RORB, RORC | RORC 3/4885CYP2C9 553/4885CYP3A4 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.